Pseudogenes: Novel Biomarkers For Identifying Tumor Subtypes?
The study by researchers at MD Anderson Cancer Center raises the possibility of using the information provided by these dysfunctional genes.
High Hurdles: Leaders of Patient Care Organizations Participating in Medicare’s ACO Programs are Pushing Ahead Into the New Healthcare
The leaders of ACOs are working their way through a welter of immediate and longer-term issues.
Aetna Sees Promise in New Heart Disease Diagnostic
With spending on diagnostics alone for cardiovascular disease likely to be a major challenge for insurers amid the baby boom wave, Aetna is turning to an emerging option as part of a strategy to avoid invasive tests and treatments.
Eradicating Silos and Improving Communication in Cancer Care
Several cancer centers have programs in place to improve communication between PCPs and oncologists.
HHS Announces the Availability of $100M in ACA Funding to Expand Access to Primary Care Through New Community Health Centers
HHS Secretary Sylvia Mathews Burwell announced today the availability of $100 million from the Affordable Care Act to support an estimated 150 new health center sites across the country in 2015.
Biomarker-Directed, MS-Based Precision Surgery for Brain Cancer
A lipid metabolite, associated with more than 70 percent of brain cancers, can help distinguish and excise cancerous tissue.
Proposed CMS Rule Expands Telehealth Payments, Domain
Wellness and behavioral health visits are among a few telehealth coverage expansions the CMS wants to add to the list of Medicare-reimbursable telehealth activities under a proposal released Thursday.
Benefits Unclear as States Rush into Medicaid Managed Care
Over the past few decades, 38 states and the District of Columbia have switched their Medicaid plans to some form of managed care for at least part of their government programs.
Nivolumab (Opdivo) Approved in Japan for the Treatment of Advanced Melanoma
Nivolumab, the first PD-1 inhibitor, was approved in Japan for treating unresectable melanoma. It has been developed in Japan by Ono Pharmaceutical, which also has rights in Korea and Taiwan.
Trametinib Receives European Approval for B-Raf–mutant Metastatic Melanoma
GSK has received marketing authorization from the European Commission for trametinib as monotherapy for unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
What’s in a Name? FDA Urged Not to Give Biosimilars Unique Names
This week, a coalition of 32 major pharmacies, health insurers, unions and pension plans asked the FDA not to require distinct names for biosimilar medications, arguing that such a move would not compromise patient safety, but could undermine the savings that are expected to be generated as these medicines are introduced into the US health care system.
Proposed Rule Would End Sunshine Act's CME Exclusion
The CMS intends to eliminate the exclusion for continuing medical education in the Open Payments program, more commonly known as the Sunshine Act, which requires drug and device companies to disclose payments to physicians.
In the Literature: Improved Chemotherapy Response Following Autophagy Inhibition in B-Raf-mutant Brain Tumors
Autophagy inhibition may improve cancer therapy, but it is unclear which tumors will benefit. BRAF mutations cause brain tumor cells to depend on autophagy and display selective chemosensitization with autophagy inhibition. We present a pediatric case in which deliberate autophagy inhibition halted tumor growth and overcame acquired BRAF-inhibition resistance.
Orteronel (TAK-700) Development Discontinued for Advanced Prostate Cancer
The lack of OS advantage is the reason for the discontinuation.
Steady Growth Forecast for Health Insurance Exchange IT Market
Operations and maintenance, plus services segments lead growth.
The Price of Prevention: Vaccine Costs Are Soaring
Vaccination prices have gone from single digits to sometimes triple digits in the last two decades, creating dilemmas for doctors and their patients as well as straining public health budgets.
AJMC Panel Asks: Does It Pay to Use Pathways?
Clinical care pathways in oncology have gained notice with WellPoint’s announcement of a $350 per patient, per month incentive. As WellPoint’s effort starts this week, The American Journal of Managed Care convened a panel with the insurer’s medical director for oncology care, ASCO President Peter Paul Yu, MD, and two other voices from the payer and provider realms to discuss how pathways are changing cancer care.
The Mammography Debate Resurfaces–This Time it's Medicare Spending
Despite increased spending, the breast cancer detection rate and stage did not change, according to a new JNCI study.
FDA's Generic-Drug Label Rule Draws Controversy
When new evidence emerges that a brand-name prescription drug has harmed patients, manufacturers are required to immediately warn doctors and consumers by updating product labels or sending letters.
States Test Medicaid ACOs to Cut Costs
Looking to control Medicaid costs, several states are launching accountable care initiatives that mirror experiments underway with Medicare and private insurers but vary significantly in their approaches.
European Regulatory Review for Merck's PD-1 Inhibitor for Advanced Melanoma
It could be the first anti-PD-1 therapy in Europe, if approved.
Amgen's Blinatumomab Receives Breakthrough Designation in ALL
Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer
UnitedHealth, an Insurer Switching Roles, Helps Hospitals on Medicare Billing
To hospitals, billions of dollars depend on how they define a patient’s stay.
Fee-For-Service Thwarts Value-Based Care's Intention
Society wants the healthcare system to improve the population's overall health while caring for the sick at a lower overall cost. The term of art is providing value-based care. Yet system leaders are stuck with a reimbursement system that still rewards volume through fee-for-service medicine.